This is a routine scientific update with no immediate trading catalyst. Monitor for dose expansion data and potential regulatory milestones for ACR-2316 and ACR-368.
Price Chart
Executive Summary
Acrivon Therapeutics announced presentations at the AACR D3 conference highlighting preclinical and early clinical data for ACR-2316, a WEE1/PKMYT1 inhibitor. The data show early partial responses across multiple AP3-predicted tumor types and a favorable tolerability profile, but no quantitative response rates or patient numbers were disclosed. This is a routine scientific update with no material financial impact.
Key Facts
- ACR-2316 is a clinical-stage WEE1/PKMYT1 inhibitor in a Phase 1/2 trial advancing toward dose expansion.
- Early clinical responses, including partial responses (PRs), observed in SCLC, sqNSCLC, adNSCLC, and endometrial cancer.
- Favorable tolerability profile with adverse events limited to transient, mechanism-based neutropenia and no non-hematological adverse events.
- Presentations at AACR D3 conference on July 22-23, 2026, focus on AP3 platform capabilities and ACR-2316 discovery.
Financial Impact
No financial data provided in the press release.
Risk Factors
- Early-stage clinical data; response rates and durability are not yet quantified.
- Competition from other WEE1 and PKMYT1 inhibitors in development.
- Need for additional clinical data to confirm differentiated profile.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3330986 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Jul 21, 2026 13w ago | Press Release | $1.68 $1.76 | ▲ +4.76% | ▲ +1.50% | $1.72 (+2.38%) |
May 22, 2026 22w ago | DEFA14A | $1.67 $2.39 | ▲ +43.11% | ▲ +40.39% | $1.72 (+2.99%) |
Apr 30, 2026 25w ago | DEFA14A | $1.85 $1.56 | ▼ −15.68% | ▼ −18.78% | $1.72 (−7.03%) |
Mar 19, 2026 31w ago | Press Release | $1.70 $1.52 | ▼ −10.59% | ▼ −24.93% | $1.72 (+1.18%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers